ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval
BioSpace
Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk's semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials.
pharminent
June 9, 2026 (Last updated: June 9, 2026)
BioSpace
Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials.
